Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion

Neuropeptides

Volumn 45, Issue 2, 2011, Pages 105-111

  Tahara, Atsuo ^a   Tsukada, Junko ^a   Tomura, Yuichi ^a   Yatsu, Takeyuki ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Mesangial cells; V1A receptor; Vascular endothelial growth factor; Vasopressin

Indexed keywords

COLLAGEN TYPE 4; NEUTRALIZING ANTIBODY; VASCULOTROPIN; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; HUMAN; HUMAN CELL; KIDNEY HYPERTROPHY; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN SECRETION;

ARGININE VASOPRESSIN; BENZAZEPINES; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE IV; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MESANGIAL CELLS; PIPERIDINES; RECEPTORS, VASOPRESSIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79951517017     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2010.12.001     Document Type: Article

References (49)

1. 3H]thymidine incorporation assay. J. Immunol. Methods 1994, 170:211-224.
2. Amemiya T., Sasamura H., Mifune M., Kitamura Y., Hirahashi J., Hayashi M., Saruta T. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int. 1999, 56:2055-2063.
3. Brenchley P.E. VEGF/VPF: a modulator of microvascular function with potential roles in glomerular pathophysiology. J. Nephrol. 1996, 9:10-17.
4. Brogi E., Wu T., Namiki A., Isner J.M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90:649-652.
5. Brown L.F., Berse B., Tognazzi K., Manseau E.J., Van de Water L., Senger D.R., Dvorak H.F., Rosen S. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int. 1992, 42:1457-1461.
6. Cha D.R., Kim N.H., Yoon J.W., Jo S.K., Cho W.Y., Kim H.K., Won N.H. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int. 2000, 77:S104-S112.
7. Collins P.D., Connolly D.T., Williams T.J. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br. J. Pharmacol. 1993, 109:195-199.
8. Cooper M.E., Vranes D., Youssef S., Stacker S.A., Cox A.J., Rizkalla B., Casley D.J., Bach L.A., Kelly D.J., Gilbert R.E. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999, 48:2229-2239.
9. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-991.
10. de Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W., Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 2001, 12:993-1000.
11. Edwards R.M., Trizna W., Kinter L.B. Renal microvascular effects of vasopressin and vasopressin antagonists. Am. J. Physiol. 1989, 256:F274-F278.
12. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
13. Finkenzeller G., Marme D., Weich H.A., Hug H. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res. 1992, 52:4821-4823.
14. Gruden G., Thomas S., Burt D., Lane S., Chusney G., Sacks S., Viberti G. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc. Natl. Acad. Sci. USA 1997, 94:12112-12116.
15. Gruden G., Thomas S., Burt D., Zhou W., Chusney G., Gnudi L., Viberti G. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J. Am. Soc. Nephrol. 1999, 10:730-737.
16. Hovind P., Tarnow L., Ostergaard P.B., Parving H.H. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000, 75:S56-S61.
17. Iijima K., Yoshikawa N., Connoly D., Nakamura H. Expression of vascular permeability factor by mesangial cells. J. Am. Soc. Nephrol. 1992, 3:514a.
18. Iijima K., Yoshikawa N., Connolly D.T., Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 1993, 44:959-966.
19. Klahr S., Schreiner G., Ischikawa I. The progression of renal disease. N. Engl. J. Med. 1998, 318:1657-1666.
20. Kurihara I., Saito T., Obara K., Shoji Y., Hirai M., Soma J., Sato H., Imai Y., Abe K. Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis. Nephron 1996, 73:629-636.
21. Leehey D.J., Singh A.K., Alavi N., Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int. 2000, 77:S93-S98.
22. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., Ulrich A. High affinity VEGF binding and developmental expression suggest Flt-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
23. Monacci W.T., Merrill M.J., Oldfield E.H. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am. J. Physiol. 1993, 264:C995-C1002.
24. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., Koide H. MRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42:450-456.
25. Nauck M., Roth M., Tamm M., Eickelberg O., Wieland H., Stulz P., Perruchoud A.P. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am. J. Respir. Cell Mol. Biol. 1997, 16:398-406.
26. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
27. Nishikawa T., Omura M., Iizuka T., Saito I., Yoshida S. Short-term clinical trial of 1-{1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl}-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Arzneimittelforschung 1996, 46:875-878.
28. Okada H., Suzuki H., Kanno Y., Saruta T. Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron 1996, 72:667-672.
29. Pedram A., Razandi M., Hu R.M., Levin E.R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J. Biol. Chem. 1997, 272:17097-17103.
30. Ryuto M., Ono M., Izumi H., Yoshida S., Weich H.A., Kohno K., Kuwano M. Induction of vascular endothelial growth factor by tumour necrosis factor alpha in human glioma cells: possible roles of SP-1. J. Biol. Chem. 1996, 271:28220-28228.
31. 2 receptor antagonist. J. Clin. Invest. 1996, 98:2729-2738.
32. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
33. Stavri G.T., Zachary I.C., Baskerville P.A., Martin J.F., Erusalimsky J.D. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation 1995, 92:11-14.
34. Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S., Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 2006, 17:3093-3104.
35. Tahara A., Saito M., Tsukada J., Ishii N., Tomura Y., Wada K., Kusayama T., Yatsu T., Uchida W., Tanaka A. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. Eur. J. Pharmacol. 1999, 368:89-94.
36. 1A receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells. Eur. J. Pharmacol. 2006, 538:32-38.
37. Tahara A., Tsukada J., Tomura Y., Suzuki T., Yatsu T., Shibasaki M. Effect of vasopressin on type IV collagen production in human mesangial cells. Regul. Pept. 2008, 147:60-66.
38. Takahashi T., Shirasawa T., Miyake K., Yahagi Y., Mayuyama N., Kasahara M., Kawamura T., Matsumura O., Mitarai T., Sakai O. Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: flt-1 and VEGF expression in renal mesangial cells. Biochem. Biophys. Res. Commun. 1995, 209:218-226.
39. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187:1579-1586.
40. Thomas S., Vanuystel J., Gruden G., Rodriguez V., Burt D., Gnudi L., Hartley B., Viberti G. Vascular endothelial growth factor receptors in human mesangium in vitro and glomerular disease. J. Am. Soc. Nephrol. 2000, 11:1236-1243.
41. Tischer E., Mitchell R., Hartman T., Sliva M., Gospodarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. J. Biol. Chem. 1991, 266:11947-11954.
42. Tsuchida K., Makita Z., Yamagishi S., Atsumi T., Miyoshi H., Obara S., Ishida M., Ishikawa S., Yasumura K., Koike T. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999, 42:579-588.
43. 1A receptor-selective antagonist. Vascul. Pharmacol. 2005, 42:47-55.
44. Williams B., Baker A.Q., Gallacher B., Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995, 25:913-917.
45. Williams B., Quinn-Baker A., Gallacher B. Serum and platelet-derived growth factor-induced expression of vascular permeability factor mRNA by human vascular smooth muscle cells in vitro. Clin. Sci. 1995, 88:141-147.
46. Williams B., Gallacher B., Patel H., Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997, 46:1497-1503.
47. Wolf G., Chen S., Ziyadeh F.N. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005, 54:1626-1634.
48. Wolthuis A., Boes A., Rodemann H.P., Crond J. Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int. 1992, 41:124-131.
49. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 1993, 90:1814-1818.